Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma

Cell Death Dis. 2014 May 22;5(5):e1244. doi: 10.1038/cddis.2014.212.

Abstract

Autophagy has an important role in tumor biology of hepatocellular carcinoma (HCC). Recent studies demonstrated that tissue factor (TF) combined with coagulation factor VII (FVII) has a pathological role by activating a G-protein-coupled receptor called protease-activated receptor 2 (PAR2) for tumor growth. The present study aimed to investigate the interactions of autophagy and the coagulation cascade in HCC. Seventy HCC patients who underwent curative liver resection were recruited. Immunohistochemical staining and western blotting were performed to determine TF, FVII, PAR2 and light chain 3 (LC3A/B) expressions in tumors and their contiguous normal regions. We found that the levels of autophagic marker LC3A/B-II and coagulation proteins (TF, FVII and PAR2) were inversely correlated in human HCC tissues. Treatments with TF, FVII or PAR2 agonist downregulated LC3A/B-II with an increased level of mTOR in Hep3B cells; in contrast, knockdown of TF, FVII or PAR2 increased LC3A/B. Furthermore, mTOR silencing restored the impaired expression of LC3A/B-II in TF-, FVII- or PAR2-treated Hep3B cells and activated autophagy. Last, as an in vivo correlate, we administered TF, FVII or PAR2 agonist in a NOD/severe combined immunodeficiency xenograft model and showed decreased LC3A/B protein levels in HepG2 tumors with treatments. Overall, our present study demonstrated that TF, FVII and PAR2 regulated autophagy mainly via mTOR signaling. The interaction of coagulation and autophagic pathways may provide potential targets for further therapeutic application in HCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Autophagy* / drug effects
  • Blood Coagulation*
  • Carcinoma, Hepatocellular / blood*
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / pathology*
  • Cell Proliferation
  • Factor VII / administration & dosage
  • Factor VII / genetics
  • Factor VII / metabolism
  • Hep G2 Cells
  • Humans
  • Liver Neoplasms / blood*
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology*
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / metabolism
  • Oligopeptides / pharmacology
  • RNA Interference
  • Receptor, PAR-2 / agonists
  • Receptor, PAR-2 / genetics
  • Receptor, PAR-2 / metabolism
  • Signal Transduction
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism
  • Thromboplastin / administration & dosage
  • Thromboplastin / genetics
  • Thromboplastin / metabolism
  • Time Factors
  • Transfection
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • MAP1LC3A protein, human
  • MAP1LC3B protein, human
  • Microtubule-Associated Proteins
  • Oligopeptides
  • Receptor, PAR-2
  • seryl-leucyl-isoleucyl-glycyl-lysyl-valinamide
  • Factor VII
  • Thromboplastin
  • MTOR protein, human
  • TOR Serine-Threonine Kinases